NasdaqGS:BBIOBiotechs
BridgeBio’s Infigratinib Data Reframes Growth Prospects In Rare Disease Franchise
BridgeBio Pharma (NasdaqGS:BBIO) reported positive Phase 3 PROPEL 3 results for oral infigratinib in children with achondroplasia.
The trial met its primary and secondary endpoints, with the highest annualized height velocity reported in a randomized achondroplasia trial and evidence of improved body proportionality.
Safety data were described as favorable, and the company plans regulatory submissions along with development expansion into hypochondroplasia.
BridgeBio Pharma, trading at...